Guest article
NPA: Setting safety limit on CBD key part of regulatory process
NPA president and CEO Daniel Fabricant, PhD, argues that FDA does not need new authorities to regulate the CBD market and that determining a safe daily intake level for the substance should be an integral part of that process.